PYC Therapeutics Sets Investor Webinar to Detail Capital Raise and Pipeline Progress

PYC Therapeutics Limited ( (AU:PYC) ) has issued an update.

PYC Therapeutics will host an investor webinar on 24 February 2026, offering shareholders an update on its recent capital raise and providing a detailed overview of the progress and outlook for each of its four drug development programs. The session, accessible both in person in Perth and online, underscores the company’s effort to maintain transparency with investors as it deploys new capital to advance its clinical-stage RNA therapy pipeline targeting monogenic genetic diseases.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing a new generation of RNA therapies for patients with genetic diseases. Leveraging a proprietary drug delivery platform designed to enhance the potency of precision medicines within the expanding RNA therapeutics class, the company is advancing drug development programs targeting monogenic diseases, which are considered to have a higher probability of clinical success.

Average Trading Volume: 490,396

Technical Sentiment Signal: Buy

Current Market Cap: A$911.3M

Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.